Trials / Recruiting
RecruitingNCT07051486
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
A Single-Arm, Multicenter Phase II Clinical Trial of SHR-A1811 for Injection in Patients With HER2-Expressing Recurrent or Metastatic Cervical Cancer Progressing After Standard Treatment
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-arm, multicenter Phase II clinical trial of SHR-A1811 for injection in patients with HER2-expressing recurrent or metastatic cervical cancer who have failed prior systemic therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1811 Injection | SHR-A1811 for injection. |
Timeline
- Start date
- 2025-10-11
- Primary completion
- 2026-02-01
- Completion
- 2026-08-01
- First posted
- 2025-07-04
- Last updated
- 2025-11-17
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07051486. Inclusion in this directory is not an endorsement.